Request for Proposals Supplement

Vendor Management Program Consultant

Date Issued: December 22, 2023
This Supplement revises the Request for Proposals (RFP) for Drug Checking & Emerging Drug Trends Consultant issued on December 7, 2023 and addresses questions submitted during the inquiry period from December 7 – December 21, 2023.

Failure to comply with any amended requirements and instructions included in this Supplement may result in a proposal being deemed non-responsive and ineligible for consideration for funding.

*Please note that only communication received in writing from the RFP Contact on behalf of the CDC Foundation shall serve to supplement, amend, or alter in any way, this RFP released by the CDC Foundation. Any other communication is not binding and should not be relied upon by any party in interpreting or responding to this RFP.*

Questions and Answers

**Q1:** Given this opportunity is jointly funded by ONDCP, I wanted to ask if 'community-based' drug checking programs fall within the scope of work of the RFA, particularly ones currently operating extra-legally?

**A1:** Yes, community-based drug checking programs are considered within the scope of the RFA. Regarding programs operating extra-legal, our hope is that a consultant would be able to provide insight on the implications and considerations of extralegal programs for our ORS teams, particularly those operating in states where these programs may be navigating within the constraints of an existing legal system.

To note, while the ORS is jointly funded by ONDCP and CDC, this consulting opportunity is funded by CDC Foundation.

**Q2:** Does the phrasing “relationship to understanding emerging drug trends” mean we should assess attitudes and beliefs along with current knowledge and skills?

**A2:** Yes, the phrasing "relationship to understanding emerging drug trends" suggests a broader perspective that goes beyond assessing current knowledge and skills. We also hope to explore attitudes and beliefs that contribute to an individual's comprehension of emerging drug trends.